Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). The company is headquartered in San Diego, California and currently employs 186 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs.). The firm's AOC platform is designed to combine the specificity of monoclonal antibodies (mAbs), with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with RNA therapeutics. The AOC platform also has the option to deploy various types of oligonucleotides, including small interfering RNA (siRNAs) and patient measure of safety (PMOs), whose specific mechanisms of action modify RNA function in different ways. The firm's pipeline includes AOC 1001, and AOC 1020. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1). AOC 1020 is designed to treat people living with facioscapulohumeral.